+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Antisense & RNAi Therapeutics Market (2022-2027) by Type, Applications, End-Users, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis

  • PDF Icon


  • 189 Pages
  • June 2022
  • Region: Global
  • Infogence Global Research
  • ID: 5635851
UP TO OFF until Dec 31st 2023
The Global Antisense & RNAi Therapeutics Market is estimated to be USD 5.22 Mn in 2022 and is expected to reach USD 10.94 Mn by 2027, growing at a CAGR of 15.94%.

Market Dynamics

Market dynamics are forces that impact the prices and behaviors of the Global Antisense & RNAi Therapeutics Market stakeholders. These forces create pricing signals which result from the changes in the supply and demand curves for a given product or service. Forces of Market Dynamics may be related to macro-economic and micro-economic factors. There are dynamic market forces other than price, demand, and supply. Human emotions can also drive decisions, influence the market, and create price signals. As the market dynamics impact the supply and demand curves, decision-makers aim to determine the best way to use various financial tools to stem various strategies for speeding the growth and reducing the risks.

Market Segmentations

The Global Antisense & RNAi Therapeutics Market is segmented based on Type, Applications, End-Users, and Geography.
  • By Type, the market is classified into RNA Interference (RNAi) and RNA Antisense.
  • By Applications, the market is classified into Genetic Disorders and Auto Immune Disorders.
  • By End-Users, the market is classified into Research Institutes and Hospitals & Clinics.
  • By Geography, the market is classified into Americas, Europe, Middle-East & Africa and Asia-Pacific.

Company Profiles

The report provides a detailed analysis of the competitors in the market. It covers the financial performance analysis for the publicly listed companies in the market. The report also offers detailed information on the companies' recent development and competitive scenario. Some of the companies covered in this report are Calando Pharmaceuticals, Inc., Gene Signal, GlaxoSmithKline PLC, Olix Pharmaceuticals, Inc., Regulus Therapeutics, Inc., Sanofi SA, Tekmira Pharmaceuticals Corp., etc.

Countries Studied

  • America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)
  • Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)
  • Middle-East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)
  • Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Ansoff Analysis

The report presents a detailed Ansoff matrix analysis for the Global Antisense & RNAi Therapeutics Market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach. The analyst analyses the Global Antisense & RNAi Therapeutics Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position. Based on the SWOT analysis conducted on the industry and industry players, the analyst has devised suitable strategies for market growth.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global Antisense & RNAi Therapeutics Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth market analysis using Porter's 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.
  • The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report also contains the competitive analysis using Positioning Quadrants, the analyst's Proprietary competitive positioning tool.

Report Highlights:

  • A complete analysis of the market, including the parent industry
  • Important market dynamics and trends
  • Market segmentation
  • Historical, current, and projected size of the market based on value and volume
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market
Frequently Asked Questions about the Global Antisense & RNAi Therapeutics Market

What is the estimated value of the Global Antisense & RNAi Therapeutics Market?

The Global Antisense & RNAi Therapeutics Market was estimated to be valued at $5.22 Million in 2022.

What is the growth rate of the Global Antisense & RNAi Therapeutics Market?

The growth rate of the Global Antisense & RNAi Therapeutics Market is 15.9%, with an estimated value of $10.94 Million by 2027.

What is the forecasted size of the Global Antisense & RNAi Therapeutics Market?

The Global Antisense & RNAi Therapeutics Market is estimated to be worth $10.94 Million by 2027.

Who are the key companies in the Global Antisense & RNAi Therapeutics Market?

Key companies in the Global Antisense & RNAi Therapeutics Market include Acuitas Therapeutics, Alnylam Pharmaceuticals, Inc., Antisense Therapeutics Ltd., Arbutus Biopharma Corp., Benitec Biopharma Ltd., Bio, Path Holdings, Inc., Calando Pharmaceuticals, Inc., Cenix BioScience and Dicerna Pharmaceuticals, Inc..

Table of Contents

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Stakeholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.1 Introduction
3.2 Market Size, Segmentations, and Outlook
4 Market Dynamics
4.1 Drivers
4.1.1 Rising Prevalence of Coronary Artery Diseases, Neurodegenerative Disorders, and Infectious Diseases
4.1.2 Target Specificity and Selectivity of Treatment
4.1.3 Initiatives from Government for Large-scale Sequencing Projects
4.2 Restraints
4.2.1 High Cost of RNA Interference-based Drugs
4.2.2 Stringent Regulations and Long Product Approval Process
4.3 Opportunities
4.3.1 Early Commercialization of Pipeline Therapeutics Rising Collaborations Between Pharmaceutical Companies
4.4 Challenges
4.4.1 Problem Regarding Antisense Technology in the Drug Delivery
5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter's Five Forces Analysis
5.3 Impact of COVID-19
5.4 Ansoff Matrix Analysis
6 Global Antisense & RNAi Therapeutics Market, By Type
6.1 Introduction
6.2 RNA Interference (RNAi)
6.3 RNA Antisense
7 Global Antisense & RNAi Therapeutics Market, By Applications
7.1 Introduction
7.2 Genetic Disorders
7.3 Auto-Immune Disorders
8 Global Antisense & RNAi Therapeutics Market, By End-Users
8.1 Introduction
8.2 Research Institutes
8.3 Hospitals & Clinics
9 Americas’ Antisense & RNAi Therapeutics Market
9.1 Introduction
9.2 Argentina
9.3 Brazil
9.4 Canada
9.5 Chile
9.6 Colombia
9.7 Mexico
9.8 Peru
9.9 United States
9.10 Rest of Americas
10 Europe’s Antisense & RNAi Therapeutics Market
10.1 Introduction
10.2 Austria
10.3 Belgium
10.4 Denmark
10.5 Finland
10.6 France
10.7 Germany
10.8 Italy
10.9 Netherlands
10.10 Norway
10.11 Poland
10.12 Russia
10.13 Spain
10.14 Sweden
10.15 Switzerland
10.16 United Kingdom
10.17 Rest of Europe
11 Middle East and Africa’s Antisense & RNAi Therapeutics Market
11.1 Introduction
11.2 Egypt
11.3 Israel
11.4 Qatar
11.5 Saudi Arabia
11.6 South Africa
11.7 United Arab Emirates
11.8 Rest of MEA
12 APAC’s Antisense & RNAi Therapeutics Market
12.1 Introduction
12.2 Australia
12.3 Bangladesh
12.4 China
12.5 India
12.6 Indonesia
12.7 Japan
12.8 Malaysia
12.9 Philippines
12.10 Singapore
12.11 South Korea
12.12 Sri Lanka
12.13 Thailand
12.14 Taiwan
12.15 Rest of Asia-Pacific
13 Competitive Landscape
13.1 Competitive Quadrant
13.2 Market Share Analysis
13.3 Strategic Initiatives
13.3.1 M&A and Investments
13.3.2 Partnerships and Collaborations
13.3.3 Product Developments and Improvements
14 Company Profiles
14.1 Acuitas Therapeutics
14.2 Alnylam Pharmaceuticals, Inc.
14.3 Antisense Therapeutics Ltd.
14.4 Arbutus Biopharma Corp.
14.5 Benitec Biopharma Ltd.
14.6 Bio-Path Holdings, Inc.
14.7 Calando Pharmaceuticals, Inc.
14.8 Cenix BioScience
14.9 Dicerna Pharmaceuticals, Inc.
14.10 Enzon Pharmaceuticals, Inc.
14.11 Gene Signal
14.12 GlaxoSmithKline PLC
14.13 Ionis Pharmaceuticals, Inc.
14.14 Lorus Therapeutics, Inc.
14.15 miRagen Therapeutics, Inc.
14.16 Olix Pharmaceuticals, Inc.
14.17 OncoGeneX Pharmaceuticals, Inc.
14.18 Quark Pharmaceuticals, Inc.
14.19 Phio Pharmaceuticals Inc.
14.20 Regulus Therapeutics, Inc.
14.21 Rexahn Pharmaceuticals, Inc.
14.22 Sanofi SA
14.23 Santaris Pharma A/S
14.24 Sarepta Therapeutics, Inc.
14.25 Silence Therapeutics
14.26 Sirnaomics, Inc.
14.27 Tekmira Pharmaceuticals Corp.
15 Appendix
15.1 Questionnaire

Companies Mentioned

  • Acuitas Therapeutics
  • Alnylam Pharmaceuticals, Inc.
  • Antisense Therapeutics Ltd.
  • Arbutus Biopharma Corp.
  • Benitec Biopharma Ltd.
  • Bio-Path Holdings, Inc.
  • Calando Pharmaceuticals, Inc.
  • Cenix BioScience
  • Dicerna Pharmaceuticals, Inc.
  • Enzon Pharmaceuticals, Inc.
  • Gene Signal
  • GlaxoSmithKline PLC
  • Ionis Pharmaceuticals, Inc.
  • Lorus Therapeutics, Inc.
  • miRagen Therapeutics, Inc.
  • Olix Pharmaceuticals, Inc.
  • OncoGeneX Pharmaceuticals, Inc.
  • Quark Pharmaceuticals, Inc.
  • Phio Pharmaceuticals Inc. Regulus Therapeutics, Inc.
  • Rexahn Pharmaceuticals, Inc.
  • Sanofi SA
  • Santaris Pharma A/S
  • Sarepta Therapeutics, Inc.
  • Silence Therapeutics
  • Sirnaomics, Inc.
  • Tekmira Pharmaceuticals Corp.